Company news
OncoSil Medical Ltd news in 2023
OncoSil Medical Ltd's news releases, calls and decks from 2023, newest first.
OncoSil receives $1.1m R&D tax incentive
December 14, 2023
First two commercial patient treatments in Greece
December 7, 2023
OncoSil onboards first patient in PANCOSIL Clinical Trial
November 28, 2023
Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer
June 30, 2023
Ethics Committee Approves PANCOSIL Clinical Trial
June 4, 2023
First patient treatment in Italy
May 21, 2023
First patient enrolled in the TRIPP-FFX Clinical Study
May 2, 2023
OncoSil to streamline operating structure
May 1, 2023
First year anniversary of the OSPREY post-marketing registry
April 30, 2023
Oral presentation at The Mayo Clinic IMPACT Course
April 23, 2023
Further commercial milestones achieved in Spain
April 23, 2023
Additional Binding Commitment Received for Entitlement Offer
April 21, 2023
Non-renounceable Rights Issue Offer Prospectus
March 19, 2023
Commitment received for Offer and updated Timetable
March 17, 2023
Entitlement Offer Presentation
March 16, 2023
Entitlement Offer to raise up to $9.9 million
March 16, 2023
Half-Yearly Report Results
February 28, 2023
Half Yearly Report and Accounts
February 28, 2023
Two key treatment centres treat first patients with OncoSil
January 30, 2023
Decks in 2023
- Shareholder Meeting (November 2023)
Shareholder meeting · 31 slides · Nov 29, 2023
- Investor Presentation (March 2023)
Investor deck · 18 slides · Mar 17, 2023